[go: up one dir, main page]

AR047719A1 - Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri - Google Patents

Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri

Info

Publication number
AR047719A1
AR047719A1 ARP040103260A ARP040103260A AR047719A1 AR 047719 A1 AR047719 A1 AR 047719A1 AR P040103260 A ARP040103260 A AR P040103260A AR P040103260 A ARP040103260 A AR P040103260A AR 047719 A1 AR047719 A1 AR 047719A1
Authority
AR
Argentina
Prior art keywords
prodrug
snri
ssri
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
ARP040103260A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR047719A1 publication Critical patent/AR047719A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un procedimiento de tratamiento de depresion en un mamífero, que incluye un ser humano, así como depresion y una enfermedad, trastorno o afeccion simultánea ejemplificados por, pero no limitados a, ansiedad, trastornos del sueno y trastornos de estrés postraumático. El procedimiento comprende la administracion al mamífero en una cantidad eficaz de una combinacion de ingredientes activos que comprenden a) un ligando alfa-2-delta (A2D) o un profármaco del mismo, o una sal farmacéuticamente aceptable de dicho ligando A2D o de dicho profármaco; y agentes activos seleccionado entre: b) un inhibidor selectivo de la recaptacion de serotonina (abreviadamente en inglés SSRI) o un profármaco del mismo o una sal farmacéuticamente aceptable de dicho SSRI o de dicho profármaco; c) un inhibidor selectivo de la recaptacion de noradrenalina (abreviadamente en inglés SNRI) o un profármaco del mismo o una sal farmacéuticamente aceptable de dicho SNRI o de dicho profármaco; y mezclas de (b) y (c). También se proporciona una composicion farmacéutica que comprende una cantidad terapéuticamente eficaz de (a) un ligando A2D o un profármaco del mismo, o una sal farmacéuticamente aceptable de dicho ligando A2D o de dicho profármaco; y agentes activos seleccionados entre: (b) un SSRI p un profármaco del mismo, o una sal farmacéuticamente aceptable de dicho SSRI o de dicho profármaco; (c) un SNRI o un profármaco del mismo o una sal farmacéuticamente aceptable de dicho SNRI o de dicho profármaco; y mezclas de (b) y (c). Los ingredientes activos preferidos para el tratamiento y la composicion farmacéutica incluyen pregabalina, gabapentina, sertralina y reboxetina.
ARP040103260A 2003-09-12 2004-09-10 Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri AR047719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50230403P 2003-09-12 2003-09-12

Publications (1)

Publication Number Publication Date
AR047719A1 true AR047719A1 (es) 2006-02-15

Family

ID=34312373

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103260A AR047719A1 (es) 2003-09-12 2004-09-10 Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri

Country Status (17)

Country Link
US (1) US20050059654A1 (es)
EP (1) EP1675582A1 (es)
JP (1) JP2007505095A (es)
KR (1) KR20060087560A (es)
CN (1) CN1878546A (es)
AR (1) AR047719A1 (es)
AU (1) AU2004271796A1 (es)
BR (1) BRPI0414347A (es)
CA (1) CA2538412A1 (es)
CO (1) CO5670327A2 (es)
IL (1) IL173901A0 (es)
MX (1) MXPA06002619A (es)
NO (1) NO20061550L (es)
RU (1) RU2006107534A (es)
TW (1) TW200520750A (es)
WO (1) WO2005025563A1 (es)
ZA (1) ZA200601551B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
CA2564994A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
CN101420947A (zh) * 2006-03-06 2009-04-29 辉瑞产品公司 用于非恢复性睡眠的α-2-δ配体
MX2009006080A (es) * 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2710538A1 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009111031A2 (en) * 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
RU2400249C1 (ru) * 2009-05-12 2010-09-27 Федеральное государственное учреждение "Новосибирский научно-исследовательский институт туберкулеза Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения преждевременной эякуляции
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
KR101129303B1 (ko) * 2011-10-19 2012-03-26 경희대학교 산학협력단 플루옥세틴을 유효성분으로 함유하는 중추신경계 질환의 예방 및 치료용 약학적 조성물
PT3189834T (pt) * 2014-09-04 2024-03-15 Sichuan Haisco Pharmaceutical Co Ltd Utilização de agente de reforço do recetor gabaa na preparação de medicamento sedativo e anestésico
LT3881845T (lt) * 2015-10-22 2025-04-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Trazodono ir gabapentino derinys, skirtas skausmo gydymui
US20220265579A1 (en) * 2019-05-15 2022-08-25 Vasthera Co. Ltd. Composition for preventing or treating cardio-cerebrovascular disease comprising autophagy activator as active ingredient

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5559004A (en) * 1994-07-12 1996-09-24 The Regents Of The University Of California Methods for screening compounds to determine calcium leak channel inhibition activity
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
GB9801538D0 (en) * 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
CA2364718C (en) * 1999-02-23 2006-07-11 Pfizer Products Inc. Monoamine reuptake inhibitors for treatment of cns disorders
TR200102850T2 (tr) * 1999-04-09 2002-03-21 Warner-Lambert Company Depresyonun iyileçtirilmesi i‡in gaba analoglarì ve trisiklik bileçiklerin kombinasyonlarì
CA2388593A1 (en) * 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
AU2001243369A1 (en) * 2000-03-14 2001-09-24 Massachusetts Institute Of Technology Composition and method to treat weight gain and obesity attributable to psychotropic drugs
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AU783516B2 (en) * 2001-04-30 2005-11-03 Warner-Lambert Company Methods, kits and compositions for using pyrrole derivatives
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
CA2491721A1 (en) * 2002-07-10 2004-01-22 Warner-Lambert Company Llc Gastrointestinal compositions comprising gaba derivatives
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004054565A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
EP1572184A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company Gabapentin analogues for fibromyalgia and other related disorders
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege

Also Published As

Publication number Publication date
IL173901A0 (en) 2006-07-05
US20050059654A1 (en) 2005-03-17
MXPA06002619A (es) 2006-06-05
KR20060087560A (ko) 2006-08-02
NO20061550L (no) 2006-04-05
ZA200601551B (en) 2007-04-25
RU2006107534A (ru) 2007-09-20
CA2538412A1 (en) 2005-03-24
TW200520750A (en) 2005-07-01
EP1675582A1 (en) 2006-07-05
WO2005025563A1 (en) 2005-03-24
CN1878546A (zh) 2006-12-13
CO5670327A2 (es) 2006-08-31
AU2004271796A1 (en) 2005-03-24
BRPI0414347A (pt) 2006-11-07
JP2007505095A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
AR047719A1 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
Pollack The pharmacotherapy of panic disorder
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
CO6241105A2 (es) "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea y un anticoagulante u otro agente antiplaquetario"
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
MX2023013040A (es) Composiciones y metodos para el tratamiento de la depresion.
CN113710319B (zh) 用于治疗焦虑相关病症的组合物和方法
EA038052B1 (ru) Комбинация, содержащая пальмитоилэтаноламид, для лечения хронической боли
Bellino et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study
CO6400019A1 (es) Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
AR012751A1 (es) Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales
CL2023001014A1 (es) Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación
AR067450A1 (es) Composicion faramaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal